Skip to main content

Table 1 Characteristics of studies included in meta-analysis

From: Adverse events of video capsule endoscopy over the past two decades: a systematic review and proportion meta-analysis

 

No. (%)

ECE

GCE

SBCE

CCE

After PCE

Overall

Total

 Included studies

26

15

303

43

15

402

 Patient, n

2469

5197

91,069

5918

2624

107,277

 VCE, n

2473

5197

91,872

5963

2574

108,079

Study characteristics

 Midpoint of study period,

mean (range)

2008

(2005–2012)

2014

(2004–2017)

2008

(2001–2018)

2012

(2006–2017)

2011

(2006–2015)

2009

(2001–2018)

 Study design

  RCT

3

1

32

6

0

42

  Prospective

23

11

81

34

7

156

  Retrospective

0

3

190

3

8

204

 Region

  Europe

12

4

122

28

6

172

  North America

11

0

64

3

1

79

  Asia

2

11

105

11

7

136

  Oceania

1

0

7

0

0

8

  Latin America

0

0

3

0

0

3

  Africa

0

0

1

0

0

1

  Multiple

0

0

1

1

1

3

Patient characteristics

 Mean age, y

55.03

48.46

53.14

55.21

33.33

52.56

 Male sex, %

65.89

57.31

51.16

52.47

51.86

52.51

 Patient groups

  Population-based

23

13

155

37

6

234

  Known IBD

0

0

23

3

7

33

  OGIB

2

2

91

1

0

96

  Abdominal pain or diarrhea

0

0

8

0

0

8

  Suspected IBD

0

0

9

0

0

9

  NSAIDs users

0

0

8

0

0

8

  Mixed high-risk group

0

0

6

0

2

8

  Suspected tumor

1

0

3

2

0

6

  1. VCE, video capsule endoscopy; ECE, esophagus capsule endoscopy; GCE, gastral capsule endoscopy; SBCE, small bowel capsule endoscopy; CCE, colon capsule endoscopy; PCE, patency capsule endoscopy; IBD, inflammatory bowel disease; OGIB, obscure gastrointestinal bleeding; NSAIDs, non-steroidal anti-inflammatory drugs